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Available online 31 March 2016Facilitated by substantial advances in analytical methods, plasma N-glycans have emerged as potential candidates
for biomarkers. In the recent years, several investigations could link aberrant plasma N-glycosylation to numerous
diseases. However, due to often limited speciﬁcity and sensitivity, only a very limited number of glycan biomarkers
were approved by the authorities up to now. The inter-individual heterogeneity of the plasma N-glycomes might
mask disease related changes in conventional large cross-sectional cohort studies, with a one-time sampling
approach. But, a possible beneﬁt of longitudinal sampling in biomarker discovery could be, that already small
changes during disease progression are revealed, by monitoring the plasma N-glycome of individuals over time.
To evaluate this, we collected blood plasma samples of ﬁve healthy donors over a time period of up to six years
(min. 1.5 years). The plasmaN-glycomewas analyzed by xCGE-LIF, to investigate the intra-individualN-glycome
variability over time. It is shown, that the plasmaN-glycome of an individual is remarkably stable over a period of
several years, and that observed small longitudinal changes are independent from seasons, but signiﬁcantly
correlated with lifestyle and environmental factors. Thus, the potential of future longitudinal biomarker discovery
studies could be demonstrated, which is a further step towards personalized diagnostics. This article is part of a
Special Issue entitled “Glycans in personalised medicine” Guest Editor: Professor Gordan Lauc.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Personalized diagnostics1. Introduction
Already in 1900Karl Landsteiner carried out a simple experiment. By
mixing serum and red blood cells from six of his colleagues he observed
agglutination. This observation he published 1901, postulating three
different blood types A, B and C (later O), as the cause of blood aggluti-
nation [1]. Since his discovery, blood became themain diagnostic source
for determining andmonitoring the physiological and biochemical state
of a patient. But, it took about 50more years of research before carbohy-
drates were identiﬁed as serologically active fragments responsible for
the different blood groups [2], and another couple of decades to develop
respective glycoanalytical methods, that enabled ﬁrst insights into the
(blood)glycome [3–9]. This reveals the enormous challenges that had
to be overcome to analyze complex carbohydrates and carbohydrate
conjugates.n personalised medicine” Guest
ynamics of Complex Technical
p).
. This is an open access article underStill during the last decade substantial advances have been made in
analytical methods and analysis software in proteomics, glycoproteomics
and glycomics, enabling more in-depth analyses of the human blood
plasma glycans and glycopeptides [6,8–18]. Especially, the development
of high-throughput (HTP) N-glycan proﬁling methods in CE, MS and
HPLC [4,6,10,19,20] facilitated enrollment of glycomics in blood biomark-
er discovery. By analyzing big cohorts, alterations in N-glycan proﬁles
from blood plasma have been found to correlate with pathological states,
such as diabetes type II [21], inﬂammation [22], liver cirrhosis/ﬁbrosis and
cancer [23–26], aswell as in breast [27–29], pancreas [30,31], ovaries [32],
prostate [33], stomach [34,35] and lung [36] cancer. Furthermore, in large
scale population studies N-glycosylation appeared to be associated with
gender and age [37–39], as well as with hormonal changes in preg-
nancy [39–41].
Despite all this tremendous work, monitoring of glycosylation alter-
ation during disease progression is still difﬁcult and especially the early
disease diagnostics turned out to be even more challenging. Due to an
often limited speciﬁcity of the found glycan biomarker, statements are
often vague and the false positive rate can be high [42–44]. As a
result only a very few biomarkers were approved by the authorities in
the past [22,29,42]. Accordingly, the limited speciﬁcity of N-glycanthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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individuals in large scale studies. This was already described by Knežević
et al. [45], focusing on variability and heritability of human plasma
N-glycome in a population study of 1008 individuals. For all above-
mentioned cross-sectional biomarker studies a single sample was
taken at only one time point from hundreds of individuals, from
healthy controls and patients suffering from the same disease.
Subsequently, a correlation analysis of the disease with the overall
plasma N-glycomes was performed, potentially impaired by variation
of different individuals [21–23,35,42,44,46,47]. Thus, trends might
have been attenuated by the differences between individuals.
This raises the questions: “Are disease caused changes really
signiﬁcant compared to the differences between individuals, and
how representative is a sample taken from a person at only one
time point, respectively, how stable is the N-glycome of a person
over time?” Up to now, only Gornik et al. showed a short term stability
of the individual humanN-glycome, by taking a time series of seven sam-
ples over ﬁve days. Furthermore, they demonstrated that the differences
between twoN-glycome samples, takenwith an interval of approximate-
ly one year, are small [48]. We here investigated for the ﬁrst time, the
long-term stability of the human plasma N-glycome of individuals, by
monitoring ﬁve healthy donors over a time period of up to six years
(min. 1.5 years), to evaluate the potential of N-glycans as biomarkers for
personalized diagnostics. Thus, for this longitudinal study, plasma
samples were taken in short intervals for one year, to evaluate seasonal
variations, followed up by sampling in larger intervals, to evaluate the
stability of the plasma N-glycome over years. Since gender, age and
smoking are identiﬁed as inﬂuencing factors [45], only non-smoking
male volunteers of the sameagewere included into the study,minimizing
the impact of these parameters. To estimate the impact of lifestyle and
environmental factors on the plasma N-glycome, parameters such as
illness, allergy, sleep behavior, as well as food and alcohol consumption
were carefully documented for each volunteer. The analysis of the
plasma N-glycome was performed by multiplexed capillary gel
electrophoreses with laser induced ﬂuorescence detection (xCGE-
LIF), also known as DNA-sequencer-adapted ﬂuorophore-assisted-
electrophoresis (DSA-FACE). In addition we are presenting here a
reﬁned annotation of N-glycan peaks for both, the native (sialylated)
and the asialo (desialylated) human plasma N-glycome. This might
help to better assess and compare published xCGE-LIF (native
plasma) [5,6,10,35,41,49,50] and DSA-FACE (asialo plasma) [23,47,
51–53] results.
2. Materials and methods
2.1. Materials and reagents
2-Picoline-borane (2-PB) (≥95%, 654213), acetic acid (AA) (for
luminescence, 45725), acetonitril (ACN) (LC–MS Grade ≥ 99.5%,
34967), aminopyrene-1,3,6-trisulfonic acid (APTS) (for ﬂuorescence,
≥96.0%, 09341), dimethylsulfoxide (DMSO) (for HPLC, ≥99.7%,
34869), IGEPAL CA-630 (IGEPAL) (for molecular biology, I8896),
phosphate buffered saline (PBS) (10× concentrated, BioReagent,
P5493-1L), Peptide N-glycosidase F (PNGase F) (BioReagent ≥95%,
P7367) and triethylamine (TEA) (≥99.5%, 471283) were obtained from
Sigma-Aldrich (Germany). Citric acid monohydrate (CA) (ACS grade for
analysis, 1002440500) was obtained from Merck-Millipore (Germany),
ethanol (EtOH) (≥99.8%, T868.3) from Carl Roth (Germany), sodium
dodecyl sulfate (SDS) (≥99%, A2572) from AppliChem (Germany) and
Bio-Gel P10 (BioGel) (150-4144) from Bio-Rad (Germany). For sample
preparation 96 well polypropylene microplates (96-W plate) (651201)
from Greiner Bio-One (Germany), 0.8 mL 96 well storage plates (96-W
storage plate) (AB-0765) from Thermo Scientiﬁc (Germany) and
AcroPrep™ 96-well GHP Filter Plates (FilterPlate) (5030) from Pall
Corporation (Germany) were used. As described in detail by Hennig
et al. [54] for xCGE-LIF analysis Hi-Di™ Formamide (HiDi) (4311320),POP-7™ Polymer (4363785), GeneScan™ 500 LIZ™ Size Standard (LIZ
standard) (4322682), MicroAmp® Optical 384-Well Reaction Plate
(384-W plate) (4309849), 384-Well plate septa (Septa) (4315934) and
16-capillary array (capillary array) (4315930) were obtained from Life
Technologies (Germany). Deionized water with R N 18.2 MΩ ∗ cm−1
(MilliQ™ water) was produced by a Gradient A10 system from Merck-
Millipore (Germany). Minivette® POCT (50 μL, K3 EDTA, 17.2113.050)
and Safety-Lancet (20–100 μL, 85.1017) were obtained from Sarstedt
(Germany). Frozen normal control plasma (VisuCon-F, FRNCP0105) was
obtained from Stago BNL (Netherlands). Octeniderm® farblos (skin disin-
fectant) was obtained from Schülke & Mayr (Vienna). Exoglycosidases
α(2-3) sialidase (Sialidase S, GK80020), α(2-3,6,8) sialidase (Sialidase
A, GK80040), α(1-2,3,4,6) fucosidase (GKX-5006) and α(1-2,3,6)
mannosidase (GKX-5010) were purchased from Prozyme (USA).
Exoglycosidases β(1-4) galactosidase (P0730L) and β(1-2,3,4,6)-N-
Acetylglucosaminidase (P0732L) were purchased from New England
Biolabs GmbH (Germany). α(1-3,4) fucosidase (E-F134) was purchased
from QA-Bio (USA).
2.2. Longitudinal sample collection
Plasma samples from healthy volunteers were obtained by a
minimal invasive sampling technique, according to a standard protocol
for dried blood spots [55]. Brieﬂy, a ﬁngertip was cleanedwith skin disin-
fectant and prickedwith a Safety-Lancet. First blood dropletwas removed
by a sterilewipe. Following dropswere collectedwith anEDTAﬁlled 50 μL
Minivette® and transferred to a 0.5mL tube. Blood plasmawas separated
by centrifugation at 1500 g for 10 min at 4 °C, transferred to new 0.5 mL
tubes and frozen until analysis at −80 °C. To avoid additional freeze
and thawing cycles, all samples were analyzed in November 2014
(storage time: two to ﬁve years — depending on the sampling time
point), except the samples from 2015 of volunteer 5.
Samples were collected from ﬁve healthy volunteers (male, non-
smoking, same age: all 28 years old in 2011) within the time course of
one year: for three months at weekly intervals, followed by three
months at biweekly and six months at monthly intervals. Additional
samples were taken within the time span of six years. Several environ-
mental factors were documented like illness, diet, allergy and alcohol
consumption (data collected for the period two days before sampling).
2.3. N-glycan release and labeling
N-glycans were released from plasma proteins as described previ-
ously [6], with slight modiﬁcations. Brieﬂy, for denaturation 2 μL of
plasma samples was mixed with 4 μL of 2% SDSPBS (w/v) (=2%
SDS:98% PBSaq) and incubated for 10 min at 60 °C. Subsequently,
remaining SDS was neutralized by adding 4 μL 8% IGEPALPBS (v/v)
(=8% IGEPAL:92% PBSaq). N-glycans were released from denatured
and linearized plasma proteins for 3 h at 37 °C by addition of 0.5 units
PNGase F in 1 μL PBSaq. Labeling of released N-glycans was performed
for 16 h at 37 °C by mixing 2 μL of N-glycan solution with 2 μL of
20 mM APTS in 3.6 M CAaq and 2 μL 0.2 M 2-PB in DMSO. To stop the
labeling reactions 100 μL of 80% ACNaq (v/v) (=80% ACN:20% MilliQ
water) was added and samples were mixed carefully.
2.4. Hydrophilic interaction chromatography based solid phase extraction
(HILIC-SPE)
Post derivatization sample clean-up was performed by HILIC-SPE to
remove free APTS, reducing agent and other impurities as published in
[54]. Brieﬂy, 200 μL of a 100 mg/mL BioGel suspension in MilliQ™
water/EtOH/ACN (70:20:10%, v/v) was applied to FilterPlate. Solvents
were removed by application of vacuum using a vacuum manifold
(Merck-Millipore, Germany). All wells were prewashed with 3 × 200 μL
MilliQ™water, followed by an equilibration with 3 × 200 μL 80% ACNaq.
APTS labeled samples were loaded onto wells containing BioGel
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prove glycan binding). For puriﬁcation wells were subsequently washed
using 5 × 200 μL 80% ACNaq containing 100 mM TEA adjusted to pH 8.5
with AA, followed by washing 3 × 200 μL 80% ACNaq. All washing steps
were performedby addition of solutions, incubation for 2min and remov-
al of solvent by vacuum. For elution 1 × 100 μL (swelling of BioGel) and
2 × 200 μL MilliQ™ water were applied to each well followed by 5 min
incubation at 500 rpm on the Thermomixer. The eluates were removed
by vacuum and collected in a 96-W storage plate. The combined eluates
were either analyzed immediately by xCGE-LIF or stored until analysis
at−20 °C (for max. 48 h).2.5. Sample measurement using xCGE-LIF
xCGE-LIFmeasurementwas performed as published [6,10,54]. Brieﬂy,
1 μL ofN-glycan eluatewasmixedwith 1 μL LIZ standard (1:50 dilution in
HiDi) and 9 μL HiDi. Themixturewas transferred to a 384-Wplate, sealed
with a septum and centrifuged for 1 min at 200 g to avoid air bubbles at
the bottom of the wells. The xCGE-LIF measurement was performed in a
3130xl Genetic Analyzer, equipped with a 50 cm capillary array, ﬁlled
with POP-7™ polymer. The samples were electrokinetically injected
and analyzed with a running voltage of 15 kV. Data was collected for
40 min.2.6. Data analysis and structural characterization
Raw data ﬁles were converted to xml ﬁle format and subsequently
analyzed using the Java-based glycan analysis software glyXtool™
(glyXera, Germany) [56]. By patented normalization to an internal stan-
dard, electropherograms were transformed to “N-glycan ﬁngerprints”
with an excellent long-term migration time reproducibility [5,54]. This
allowed automated peak picking, integration and relative quantiﬁca-
tion, but also structural assignment of N-glycan peaks by migration
time matching to an in-house N-glycan database, containing more
than 300 N-glycan entries [6,10,50].
To conﬁrm N-glycan sequences and linkages, exoglycosidase digests
were performed using the enzymes α(2-3) sialidase (SiaS), α(2-3,6,8)
sialidase (SiaA), α(1-3,4) fucosidase (a34FUCase), α(1-2,3,4,6)
fucosidase (aFUCase), β(1-4) galactosidase (b14GALase), α(1-2,3,6)
mannosidase (aMANase) and β(1-2,3,4,6)-N-Acetylglucosaminidase
(bNAcGLUase). Exoglycosidasedigestionswereperformedunder reaction
conditions recommended by the suppliers. All enzymes were carefully
tested for reactivity and speciﬁcity by incubation with APTS labeled
N-glycans derived from bovine fetuin (for SiaA, SiaS), bovine IgG
(for aFUCase, b14GALase and bNAcGLUase), bovine ribonuclease B
(for aMANase) and human lactotransferrin (for a34FUCase) (data
not shown).2.7. Statistics
All samples were analyzed in a randomized sequence. Due to the
high reproducibility of the method no batch correction had to be per-
formed. Relative peak height proportion (rPHP), standard deviations
(SD) and coefﬁcients of variation (CV) were calculated as published in
[57]. The horizontal line within the box plot (see Figs. 3–5) indicates
the median, boundaries of the box mark the upper and lower quartile
(Q1 = 25%, Q3 = 75%, Box = interquartile range (IQR)). The whiskers
indicate Q1 — (1.5xIQR) and Q3 + (1.5xIQR). The mean value is
illustrated by a square within the box. Normality of distribution
was checked by a Kolmogorov–Smirnov test using Origin 8.6.0.
Because of non-normal distribution found with some variables, for
the comparison of two groups a nonparametric Mann–Whitney U-test
was performed using Origin 8.6.0. p-Values b0.05 were considered to
be statistically signiﬁcant.3. Results
3.1. Subject characteristics and longitudinal sampling procedure
To minimize the variability and the effect of environmental factors in
this study, plasma sampleswere longitudinally collected from individuals
of the same gender and age, sharing a very similar lifestyle. In contrast
to the design of other studies, where the plasma N-glycosylation was
evaluated for a big number of individuals at only one time point, this
study focuses on the evaluation of the long-term stability of the plasma
N-glycosylation, collecting samples of a small number of individuals at
multiple time points over a long period of time. During this longitudinal
sampling, 135 EDTA-plasma samples were collected from ﬁve healthy
volunteers (V1, V2, V3, V4 and V5) within a timeframe of 1.5 up to six
years (V1: n = 22, t = 2 yrs.; V2: n = 29, t = 1.5 yrs.; V3: n = 31, t =
2 yrs.; V4: n = 22, t = 1.5 yr.; V5: n = 31; t = 6 yrs.).
3.2. Reﬁned peak annotation of native and asialo humanplasmaN-glycome
The native human plasma N-glycome was generated by releasing
N-glycans from frozen normal control plasma using PNGase F. Released
N-glycans were treated and subjected to xCGE-LIF based glycoanalysis
as described above. The asialo human plasmaN-glycomewas generated
by SiaA treatment of native plasma N-glycome before xCGE-LIF mea-
surement. The 31 most abundant peaks of the native N-glycan ﬁnger-
print, respectively the 21 most abundant peaks for the asialo N-glycan
ﬁngerprint, were picked as shown in Fig. 1. Peaks were annotated via
N-glycan database matching, as described above. To conﬁrm these
structural assignments various exoglycosidase digests were performed
using SiaS, SiaA, a34FUCase, aFUCase, b14GALase, aMANase,
bNAcGLUase, as exemplarily shown in Fig. S1. Compared to previous
publications [6,23,41,47], a reﬁnement of the peak annotation was
achieved for the native and asialo plasma N-glycome. Annotated N-
glycans, which contribute a substantial proportion to the peak height,
are given in Table 1.
The high resolution of xCGE-LIF allows to differentiate between ter-
minal α(2-3) and α(2-6) linked N-acetylneuraminic acids (e.g. Fig. 1
and Table 1: peak 2 vs. 3, peak 4 vs. 6 and peak 7 vs. 9 vs. 10), as well
as betweenα(1-6) linked core fucose andα(1-3) linked antenna fucose
(e.g. Fig. 1 and Table 1: peak 17 vs. 18, peak XI vs. XII and peak XVI vs.
XVII). Hence, this feature even enables the identiﬁcation of N-glycans
with LewisX and Sialyl-LewisX motifs (e.g. Fig. 1 and Table 1: peaks 5,
8, 16 and peaks XI, XVI, XVIII).
3.3. Precision of the glycoanalytical procedure
To evaluate the reproducibility of the method, respectively to deter-
mine the variability associated with the sample preparation, the whole
analytical procedure (N-glycan release, APTS labeling, HILIC-SPE and
xCGE-LIFmeasurement)was repeated independently 10 times (on differ-
ent days), by different persons, in different labs, in technical triplicates,
using frozen normal control plasma. The 31 most abundant peaks of
the N-glycan ﬁngerprints of the native human plasma N-glycome were
picked by glyXtool™ and their rPHPs were calculated as published by
Kottler et al. [57]. Averages, SDs and CVs of those rPHPs are given in
Table 2. While the biggest rPHP CV for low abundant peaks (b0.5%
rPHP) is up to 11%, the rPHP CV for medium to high abundant peaks
(N2.5% rPHP) is only up to 3%. The average rPHP CV for all peaks is
only about 5.4%, which demonstrates the good reproducibility of
the method. Furthermore, the rPHP reproducibility of the xCGE-LIF
measurement was evaluated, running the same sample 40 times
within the timeframe of one year. An average rPHP CV of 1.7%
(Table S1) shows the very high reproducibility of the xCGE-LIF mea-
surement, in spite of the use of different batches of separation polymer
and capillary arrays.
Fig. 1. xCGE-LIF generated human plasmaN-glycan ﬁngerprints. Signal intensity in relativeﬂuorescence units [RFU] is plotted over the normalizedmigration time [MTU″]. A— Fingerprint
of native (sialylated) frozen normal control plasma-derivedN-glycome, labeledwith APTS and analyzed by xCGE-LIF. B— Fingerprint of desialylated frozen normal control plasma-derived
N-glycome, labeled with APTS and analyzed by xCGE-LIF. Numbers indicate the 31, respectively the 21 most abundant N-glycan peaks, picked within the N-glycan ﬁngerprints. The
annotation of the picked peaks can be found in Table 1. The inset (subﬁgures in A and B) show the entire migration time range of the xCGE-LIF measurement.
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individuals
To determine the variability of the human plasma N-glycosylation
135 samples from ﬁve volunteers were analyzed using the described
xCGE-LIF workﬂow. The 31 most abundant peaks within the N-glycan
ﬁngerprints of native human plasma N-glycomes were picked and
their rPHPs, as well as their SDs were calculated. The results were
grouped per volunteer and compared in Fig. 2 (data in Table S2).
While the variation for a single person over several years is intriguingly
small, the difference between the volunteers is rather big. For instance,
the average rPHPover time of peak 4 for V1 is 37% (SD: 3%),whereas the
average rPHP over time for the same peak for V5 is only 27% (SD: 4%).
Comparing the rPHP over time for all volunteers, a lower degree of
sialylation can be observed for V5. Peak 4, mainly composed of
A2G2S2(2,6) (see Table 1), reveals to be quite small for V5, whereas
its partially sialylated (A2G2S1(2,6), peak 19) and non-sialylated
(A2G2, peak 28) forms are rather big. The same holds true for A3G3S3
(peak 2) and its partially sialylated counterpart A3G3S2 in peaks 13,
14 and 15.
To determine the seasonal variation and the long-term stability of the
human plasma N-glycosylation, the 135 samples from ﬁve volunteers
were grouped and sorted by date. To give an overview, in Fig. 3
the rPHPs of three peaks, comprising a low, middle and high abundantN-glycan, were plotted against the time. For the sake of clarity, the
time course is only shown for V3 (blue circles) and V5 (red squares).
For both volunteers no seasonal trends are visible within the timeframe
of one year. Furthermore, the rPHPs of all three peaks are remarkably
stable over several years. However, despite this long-term stability,
the box plots of the two volunteers show different variabilities. The
rPHPs of V5 show a smaller variability than the rPHPs of V3, although
the variability of a single volunteer over time is always far below the
variability of the entire group (indicated by the three box plots in Fig. 3).
3.5. Inﬂuence of environmental factors on the native human plasma N-
glycome of individuals
For each volunteer the parameters illness, allergy, sleep behavior, as
well as food and alcohol consumptionwere carefully documented, to in-
vestigate the inﬂuence of lifestyle and environmental factors on human
plasma N-glycome variability of an individual over time. To establish a
relationship between event and response, all samples of one event of a
volunteer over time were grouped and compared to the group of its
counterpart out of his time series (e.g. common cold vs. healthy status
or normal sleep vs. lack of sleep). A sample was assigned to a certain
group only, if the event (e.g. sports injury) took place max. two days
before sampling. The statistical signiﬁcances between groups were
evaluated by a Mann–Whitney U test for all 31 N-glycan peaks of the
Table 1
N-glycan structures assigned to the peaks of the native and asialo human plasmaN-glycan
ﬁngerprint of Fig. 1.
Symbolic representation of N-glycan structures were drawn with GlycoWorkbench Ver-
sion 1.1, following the guideline of the Consortium for Functional Glycomics [58]. Glycan
names are based on Oxford nomenclature (modiﬁed to our needs). The 31, respectively
21most abundant peaks inside the native, or asialo human plasma N-glycome ﬁngerprint
were annotated viaN-glycan databasematching and conﬁrmed by various exoglycosidase
digests, using SiaS, SiaA, a34FUCase, aFUCase, b14GALase, aMANase, bNAcGLUase.
Peak N-glycan name N-glycan structure Peak N-glycan name N-glycan
structure
1 A4G4S4(2,6) I Man5
2 A3G3S3(2,6) II Man6
3 A3G3S1(2,3)S2(2,6) III FA2G0
FA1G1[6]
4 A2G2S2(2,6) IV FA1G1[3]
5 A3F(3)G3S1(2,3)S2(2,6) V FA2BG0
6 A2G2S1(2,6)S1(2,3) VI FA2G1[6]
7 FA2G2S2(2,6) VII FA2G1[3]
8 A2F(3)G2S1(2,6)S1(2,3) VIII A2G2
FA2BG1[6]
9 FA2BG2S2(2,6)
FA2G2S1(2,3)S1(2,6)
IX Man8
FA2BG1[3]
10 FA2G2S2(2,3)
A4G4S2(2,3)S1(2,6)
X A2BG2
11 FA1G1S1(2,6)[3]
FA1G1S1(2,3)[6]
A2G1S1(2,6)[6]
XI A2F(3)G2
12 A2G1S1(2,6)[3]
A4F(3)G4S1(2,3)S2(2,6)
XII FA2G2
Man9
13 A3G3S2(2,6) XIII FA2BG2
14 A3G3S1(2,3)S1(2,6) XIV A3G3[2,6]
15 A3G3S1(2,3)S1(2,6) XV A3G3[2,4]
16 A3F(3)G3S2(2,6) XVI A3[2,4]F(3)G3
17 FA2G1S1(2,6)[3]
FA3G3S2(2,6)
XVII FA3[2,4]G3
18 A3F(3)G3S1(2,3)S1(2,6)
FA2G1S1(2,3)[6]
FA2BG1S1(2,6)[6]
XVIII FA3[2,4]F(3)G3
25 FA2BG0
26 FA2G1[6]
27 FA2G1[3]
28 A2G2
FA2BG1[6]
29 Man8
FA2BG1[3]
30 FA2G2
Man9
31 FA2BG2
19 A2G2S1(2,6)
FA2BG1S1(2,6)[3]
XIX A4G4
20 FA2G2S1(2,6)
Man5
XX A4F(3)G4
21 FA2BG2S1(2,6)
FA2G2S1(2,3)[6]
XXI FA4G4
22 FA2G2S1(2,3)[3]
23 Man6
24 FA2G0
A3G3S1(2,6)
Table 1 (continued)
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subclasses (Table S3). N-glycan classes and subclasses were built
based on N-glycan properties, like neutral, sialylated, bisected, core
fucosylated, biantennary and triantennary. A complete list of N-glycan
classes and subclasses and their associated peaks can be found in
Table S4.
E.g., V4 had several sport injuries during the sampling period. To
evaluate the inﬂuence of this factor on the plasma N-glycome, the V4
sports injury samples over time were compared to his healthy control
samples out of his time series. In case of sports injury the proportion
of sialylated N-glycans increased signiﬁcantly from 79.4% to 81.2%
(Fig. 4B), while the proportion of neutral N-glycans inside the N-
glycan ﬁngerprint dropped signiﬁcantly from 19.4% to 17.6% (Fig. 4A).
But, comparing the V4 sports injury sample group with the group of
all healthy volunteers over time, no signiﬁcant changes can be observed
(Fig. 4A and B, blue box plot). To evaluate if the subclasses of neutral N-
glycans are affected by sports injury, the change of fucosylated and
bisected N-glycans was plotted in Fig. 4C and D. Apparently, both sub-
classes are showing the same trend, a signiﬁcant decrease in case of
the sports injury. Besides this, also an inﬂuence of sports injury on the
degree of galactosylation could be found. While the ratio of FA2G0 to
neutral complex N-glycans (Peak 24/sum(Peaks 24–31)) decreased
with p b 0.05, the ratio of the FA2G2 to neutral complex N-glycans
(Peak 30/sum(Peaks 24–31)) increased slightly with p b 0.05 (see
Table S3), indicating a raised galactosylation after sports injury.
Table 2
Precision of the glycoanalytical procedure. Frozen normal control plasma was indepen-
dently analyzed (N-glycan release, labeling, puriﬁcation and xCGE-LIF measurement) at
10 different days, each time in technical triplicates (n = 30). Within the xCGE-LIF gener-
ated native plasma N-glycan ﬁngerprints the 31 most abundant peaks were picked and
their relative peak height proportions (rPHP) were calculated. To evaluate the precision
of the analytical procedure, the average rPHP was calculated for each peak, as well as its
standard deviation (SD) and its coefﬁcient of variation (CV).
Peak no. rPHP in % SD CV in %
1 1.80 0.06 3.11
2 0.83 0.07 8.56
3 4.62 0.13 2.76
4 37.11 0.47 1.26
5 2.86 0.11 3.76
6 3.44 0.08 2.33
7 6.66 0.25 3.81
8 0.37 0.04 10.36
9 3.21 0.13 3.91
10 1.13 0.03 2.70
11 0.18 0.02 11.20
12 0.28 0.03 11.29
13 0.57 0.03 4.80
14 0.60 0.04 7.39
15 0.30 0.03 9.20
16 0.40 0.04 11.02
17 0.82 0.04 4.64
18 0.31 0.03 11.21
19 11.33 0.36 3.14
20 4.96 0.14 2.83
21 2.57 0.07 2.62
22 0.56 0.02 4.00
23 0.85 0.03 3.07
24 3.60 0.21 5.89
25 0.80 0.04 5.51
26 3.28 0.20 6.25
27 1.54 0.10 6.49
28 1.16 0.05 4.18
29 0.37 0.01 3.76
30 2.93 0.13 4.40
31 0.56 0.02 3.32
Average rPHP CV: 5.44
1733R. Hennig et al. / Biochimica et Biophysica Acta 1860 (2016) 1728–1738In a second example the inﬂuence of a common cold on the native
human plasma N-glycan composition is shown. V5 suffered several
times from a common cold during the sampling period, resulting in a
signiﬁcant decrease of diantennary plasma N-glycans (Fig. 5A) and
a signiﬁcant increase of triantennary plasma N-glycans (Fig. 5B).
Apparently, suffering from a pollen allergy had the same effect on the
plasmaN-glycan composition of V5, decreasing the level of diantennary
N-glycans (Fig. 5C) and increasing the level of triantennary plasma N-
glycans (Fig. 5D).
4. Discussion
Since for large-scale biomarker discovery studies usually plasma N-
glycosylation is evaluated for samples taken from a large number of
individuals but only at one time point [21–23,35,42,44,46,47], the
questions arise: “Are disease caused changes really signiﬁcant com-
pared to the differences between individuals, and how representative
is a single sample taken from one person at only one time point, respec-
tively, how stable is the N-glycome of a person over time?” Gornik et al.
proved in 2009 that everyday activities have no global effects on the
protein N-glycosylation of human plasma, attesting a high intraday
and interday stability of the plasma N-glycome [48]. Nevertheless,
the inﬂuence of weekly, monthly or seasonal events on the plasma
N-glycome stability was not evaluated by them. Thus, to estimate
the diagnostic potential of the plasma N-glycome as a biomarker,
we monitored its long-term stability over a time period of up to six
years, by collecting samples of a small number of individuals, but at
multiple time points.In order to properly assess the results of our long-term stability
study we initially determined the precision of the analytical procedure
by a reproducibility test. Therefore, a sample was analyzed indepen-
dently 10 times in triplicates (Table 2). The obtained average rPHP CV
of 5.4% indicates a high precision of the analytical procedure, which is
absolutely comparable with other state-of-the-art N-glycan analysis
techniques [59] (HILIC-HPLC: 4.3% [45], MALDI-TOF: below 6% or 8%
[60], HPLC-MS: below 5% [61]). In particular, repeated xCGE-LIF based
measurements with an average rPHP CV of only 1.7% (Table S1) are
demonstrating its high reproducibility and competitiveness. This
further indicates that sample preparation is themajor origin of variation
of the method.
To evaluate variability, respectively, the long-term stability of the
native human plasma N-glycome, we analyzed samples of ﬁve healthy
volunteers collected in a timeframe of up to six years (Fig. 2 and
Table S2). The long-term stability measured by the average rPHP CV of
all peaks was between 8.5% (analyzing 31 samples collected over six
years from V5) to 11.4% (analyzing 31 samples collected over two
years from V3). This surprisingly small variability, which was only
slightly above the variability of the analytical procedure, demonstrates
the impressive long-term stability of individual human plasma N-
glycomes. However, the variability was not equally distributed over all
peaks. Notably, for all volunteers peaks 2, 11 and 15 show a higher
rPHP variability, and thus are indicating that the underlying N-glycan
structures are probably stronger regulated and quite sensitive to life-
style and environmental factors (Table S2). This variabilitymight reﬂect
changes in concentration of certain plasma proteins, which still need to
be determined. In contrast, the rPHPs of neutral complex N-glycans
(peaks 24–31, mainly related to IgG [16]) are quite stable, or rather
insensitive to environmental factors. While the temporal variability of
the N-glycome of a single volunteer was shown to be rather small
over several years, the differences between the individuals can be
remarkably big (see Figs. 2 and 3). Due to the fact that all volunteers
share quite similar features (e.g. gender, age and lifestyle), this big
differences in the N-glycome can only be explained by a strong inﬂu-
ence of the genetic background. This ﬁnding is consistent with the
study of Knezevic et al. analyzing the plasma N-glycome of 1008 indi-
viduals [45]. In contrast, the difference in rPHP between the volunteers
are smaller for the asialoN-glycome (Table S5), indicating the inﬂuence
of sialylation as amajor contributor of variability. A performedGlycoAge
Test on the asialo N-glycome resulted in values from−0.4 to−0.5 for
all volunteers (Table S5), which is in good agreementwith the previously
published values of a healthy Belgian population [52].
Finally, we attempted to identify the origin of the N-glycome vari-
ability. To visualize whether the plasma N-glycome undergoes seasonal
ﬂuctuations, the rPHPs of three selected peaks were plotted over the
time for V3 and V5 (Fig. 3). Apparently, these representative examples
show no signiﬁcant seasonal ﬂuctuations of the N-glycome. To evaluate
whether the small observed variability is caused by certain events like
illness or allergy, we performed a correlation analysis of the documented
lifestyle and environmental factors with the changes in the human
plasma N-glycome. V4 had several sport injuries during the sampling
period, associated with sprain and bruises of joints, thus local inﬂamma-
tion. It is known that a large number of blood glycoproteins are synthe-
sized by the liver and B-lymphocytes [8,16], hence changes in the
serum total N-glycan compositions could reﬂect an alteration of the
liver or B-lymphocyte physiology [23]. Nevertheless, as a response to
local and systemic inﬂammation (e.g. a septic shock), the liver produces
a large number of acute-phase proteins, secreted into the bloodstream.
These acute-phase proteins are highly sialylated [13,16], increasing the
overall percentage of sialylated N-glycans inside the blood plasma [62,
63]. Apparently, as displayed in Fig. 4, this is consistent with observations
for V4. In case of sports injury the proportion of sialylated N-glycans
increased signiﬁcantly (Fig. 4B), while the proportion of neutral N-
glycans decreased signiﬁcantly (Fig. 4A). Although both effects are
small, the grouped sports injury samples of V4 can be clearly separated
Fig. 2. Bar plot for the comparison of the average relative peak height proportions (rPHP) from ﬁve individuals over time. To evaluate the variation of human plasmaN-glycome between
individuals, the native human plasma N-glycome of in total 135 samples was analyzed. Samples, originated from ﬁve healthy volunteers (V1–V5), were sampled over a time period of at
least one year (V1 (black): n= 22, t= 2 yrs.; V2 (gray): n= 29, t= 1.5 yrs.; V3 (blue): n= 31, t= 2 yrs.; V4 (white): n= 22, t= 1 yr.; V5 (red): n= 31; t= 6 yrs). from the generated
N-glycan ﬁngerprints the 31 most abundant peaks were picked and its rPHPs were calculated. For the bar plot all longitudinal samples of one volunteer were grouped and the average
rPHP, as well as its SDwere calculated. For example, peak 4 of volunteer 5 (red) had an average rPHP (i.e. a relative abundance) of 27% over six years, with a SD of 4% (exact values
can be found in Table S2). One representative xCGE-LIF generated human plasma N-glycan ﬁngerprint of each volunteer, as well as an overlay of those, can be found in supplementary
Fig. S2.
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large variability between individuals, the sports injury group cannot be
separated from the healthy control group comprising the data from all
ﬁve volunteers (Fig. 4A, red vs. blue box plot). This could explainwhy gly-
can biomarkers from large-scale studies, where samples are taken from a
large number of individuals— but only at one time point, often have only
a limited speciﬁcity. Furthermore, a small, but signiﬁcant increase of the
galactosylation degree could be observed in case of sports injury
(Table S3). Since a big proportion of the neutral complex N-glycans in
human plasma are derived from IgG [16], an increase of the
galactosylation presumably implies an increase of IgG galactosylation,
which is described in literature to have an anti-inﬂammatory/
immunosuppressive function [40,64]. In a second example V5 suffered
several times during the sampling period from a common cold. A signif-
icant decrease of diantennary N-glycans and signiﬁcant increase of
triantennary N-glycans could always be observed in case of illness
(see Fig. 5). The origin of this effect can only be explained by identifying
triantennary N-glycans-containing plasma proteins and looking at their
functions. In the review of Clerc at al. [16] alpha-1-acid glycoprotein
(AGP) and alpha-1-antitrypsin (AAT) are declared to be one of the
main contributors of triantennary N-glycans in the human plasma N-
glycome. Both proteins aremainly produced by the liver, being involved
in the defense of the body against respiratory infections. For example
AGP is an acute-phase protein, known as a negative modulator of
inﬂammation, whereas AAT acts as inhibitor of a wide range of serine
proteases. Due to its small size and its hydrophilicity AAT can easily
move into tissue ﬂuids, such as mucus of lungs, preventing the proteo-
lytic destruction of the lower respiratory tract [65]. Hence, the higherproduction of AAT and AGP as a response to the inﬂammation of
respiratory tract during the common cold could be an explanation for
the increased levels of triantennary plasma N-glycans.
In both examples a signiﬁcant change over time in the composition
of the plasma N-glycome of one individual could be detected. In case
of sports injury (Fig. 4), the disease related changes are small and not
signiﬁcant compared to the healthy control group. Consequently, due
to the big inter-individual differences, small but signiﬁcant changes
might have been undetected, when looking only at a single time point
of a large cohort. The second case shows a different characteristic. A
signiﬁcant decrease of diantennary N-glycans during a common cold
could be observed for V5 (p b 0.05), as well as for the healthy control
group (p b 0.01) (Fig. 5A). However, a signiﬁcant decrease of diantennary
N-glycans could also be observed comparing the healthy status of V5with
the healthy control group (p b 0.01). This means, the already low sta-
tus of diantennary N-glycans in plasma of V5 (see Table S5) results in
a false positive detection of a healthy V5 as diseased. The same holds
true for the triantennary N-glycans during a common cold for
V5 (Fig. 5B), due to naturally elevated levels of triantennary plasma
N-glycans for V5.
5. Conclusion and outlook
Here, we present a sophisticated method to analyze the human
plasma N-glycome, based on xCGE-LIF. The straightforward sample
preparation, in a 96 well format in combination with the multi-
capillary gel electrophoresis system, enables the analysis of hun-
dreds of samples in real high throughput. Due to the high sensitivity
Fig. 3. Evaluation of the intra-individual and inter-individual variability of the plasma N-glycome. A— To illustrate the variability of human plasma N-glycome within individuals (intra-
individual variability), exemplarily the rPHP of three peaks (high, middle and low abundant) was plotted over the sampling time points (volunteer 3—blue circles; volunteer 5—red
squares). An overlay of the native plasma-derived N-glycome ﬁngerprints of volunteer 5 can be found in supplementary Fig. S3. B — Comparison of the intra-individual (one donor:
V3, middle box plot; V5, left box plot) with the inter-individual (all donors, right box plot) variability of the N-glycome. The box plot was generated by including the rPHP of all sampling
time points (V3 and V5: n= 31; all volunteers: n = 135), thereby each sample is represented as a circle inside the box plot. Parameters of the box plot visualization (e.g. boundaries and
whiskers) are deﬁned within the “Statistics” section. Underlying data, as well the data of all other volunteers can be found in Table S2.
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only a single droplet of capillary blood from a ﬁngertip. The superior
resolution of the xCGE-LIF measurement and a reﬁned peak annotation
for the native and asialo plasma N-glycome, will enable to monitor a
bigger number of N-glycan motifs (like LewisX and Sialyl-LewisX) in
the future.
Via a long-term stability study of the native plasma N-glycome, it
could be demonstrated that the individual's N-glycome is remarkably
stable over a period of several years and independent from seasons. Fur-
thermore, it could be demonstrated that the inter-individual differences
of theN-glycome are enormous, but by looking at the progression of the
plasma N-glycome of a single person, small changes could be detect-
ed and linked to lifestyle and environmental factors. Consequently,
taking time-series from individuals can be beneﬁcial compared to
large-scale studies, where samples are taken from a large number
of donors (but only once). In such cross-sectional studies, small dis-
ease related changes in the N-glycome would be hidden within the
population variation, caused by the inter-individual differences of
the N-glycome.
Our future aim is to further evaluate and validate these initial results
with longitudinal studies of larger sample cohorts. Especially, the inﬂu-
ence of various environmental factors on the plasma N-glycome needs
to be evaluated, leading to personalized longitudinal plasma N-glycan
ﬁngerprints (plPNF), which contain information about the individual
“normal” N-glycan composition in combination with its longitudinal
variability. Subsequently, this information could be used to detect
even small disease associated temporal changes in glycosylation,which are above the individual longitudinal variability of the plPNF.
Finally, this will increase the predictive strength of glycan biomarkers,
making them to a powerful tool in personalized diagnostics.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbagen.2016.03.035.Transparency document
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Fig. 4. Injury-related changes in the abundance of different N-glycan classes and subclasses for volunteer 4. All samples of volunteer 4, each time taken after a sports injury (red box plot,
n=7), were grouped and compared to the healthy control samples of volunteer 4 (green box plot, n=15), and to the healthy control samples of all volunteers (blue box plot, n=100). A
—Boxplots of theneutral complexN-glycan class (sumof peaks 24–31). B— Box plots of the sialylated complexN-glycan class (sumof peaks 1–22). C— Box plots of theneutral fucosylated
complex N-glycan subclass (sum of peaks 24–31). D— Box plots of the neutral bisected complex N-glycan subclass (sum of peaks 25, 28, 29, 31). Parameters of the box plot visualization
(e.g. boundaries and whiskers) are deﬁned within the “Statistics” section. The underlying data can be found in Table S3.
Fig. 5. Common cold andpollen allergy related changes in the abundance of differentN-glycan classes for volunteer 5. All samples of volunteer 5, takenduring a common cold (A and B: red
box plots, n= 6) and during pollen allergy (C and D: red box plots, n= 4)were grouped and compared to the healthy control samples of volunteer 5 (A and B: green box plots, n= 25; C
and D: green box plots, n=27), and to the healthy control samples of all volunteers (A–Dblue box plots, n= 100). A and C— Box plots of the diantennary complexN-glycan class (sumof
peaks 4, 6–12, 17–22, 24–31). B and D— Box plots of the triantennary complex N-glycan class (sum of peaks 2, 3, 5, 13–18). Parameters of the box plot visualization (e.g. boundaries and
whiskers) are deﬁned within the “Statistics” section. The underlying data can be found in Table S3.
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